Mercury Bio Appoints Cassandra Perkins as VP of Corporate Strategy to Enhance CNS Therapeutics

Mercury Bio Strengthens Leadership with New VP of Corporate Strategy

Mercury Bio, a pioneering company in the field of intracellular delivery for central nervous system (CNS) therapeutics, announces the appointment of Cassandra "Casey" Perkins as Vice President of Corporate Strategy & Business Development. With an extensive background spanning over 25 years in biotech and pharmaceuticals, Perkins brings a wealth of experience that aligns with Mercury Bio's strategic objectives. Her expertise in commercial strategy, market access, and patient services, particularly in the niche of rare and orphan diseases, positions her as a valuable asset in advancing Mercury Bio's proprietary yEV™ platform. This platform specializes in utilizing yeast-derived exosomes to enable the transfer of proteins and RNA between cells, a critical innovation for the treatment of neurological disorders.

In her new role, Perkins is tasked with overseeing corporate strategy and business development, with a focus on building strategic partnerships and enhancing investor relations. The yEV™ platform has recently demonstrated promising pre-clinical results, particularly in the effective delivery of nanobodies across the blood-brain barrier in murine models. These findings highlight the platform’s potential to open new therapeutic avenues for treating conditions such as Alzheimer’s and Parkinson’s diseases. Perkins’ prior experience in the commercialization of innovative therapies, including ZOLGENSMA®, underscores her capability to navigate the complex landscape of CNS therapeutics and drive Mercury Bio's mission forward.

Perkins will work closely with key executives, including Chief Scientific Officer Richard Sayre, Ph.D., and CEO Bruce McCormick, to showcase the capabilities of the yEV™ platform at the upcoming Biotech Showcase in San Francisco, CA. This event marks an important opportunity for Mercury Bio to engage with industry stakeholders and investors, and to position itself as a leader in the evolution of drug delivery mechanisms for CNS treatments. The company views Perkins' appointment as a critical step in its ongoing efforts to enhance its therapeutic technologies and expand its product pipeline.

In addition to Perkins’ appointment, Mercury Bio continues to focus on its innovative research initiatives, which are essential for addressing unmet medical needs in the CNS domain. The company's advancements in exosome technology offer the potential to significantly improve the efficacy of CNS therapeutics, setting the stage for future breakthroughs in treatment options. As the biotech landscape evolves, Mercury Bio remains committed to navigating challenges in the industry while prioritizing patient-centered solutions.